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Abstract
Aims: The aim of this study was to evaluate the efficacy and safety of 24-month vs. six-month dual anti-
platelet therapy (DAPT) among elderly (≥75 years) and non-elderly patients (<75 years) undergoing percu-
taneous coronary intervention.
Methods and results: The primary efficacy endpoint of the PRODIGY trial was the composite of death, 
myocardial infarction, or cerebrovascular accident at 24-month follow-up. The key safety endpoint was 
type 2, 3 or 5 bleeding according to the BARC criteria. Of 1,970 participants, 587 (29.8%) were elderly and 
had a higher risk of adverse events compared with younger patients. The risk of the primary endpoint was 
not significantly reduced with 24-month compared to six-month DAPT among both elderly (HR 0.80, 95% 
CI: 0.55-1.16, p=0.24) and non-elderly patients (HR 1.48, 95% CI: 0.95-2.30, p=0.08), although interac-
tion testing was significant (p=0.036). A 24-month versus six-month DAPT significantly increased the risk 
of BARC type 2, 3 or 5 bleeding in both older (HR 1.90, 95% CI: 1.06-3.38, p=0.03) and younger patients 
(HR 2.54, 95% CI: 1.43-4.53, p=0.002, p-interaction=0.48). However, measures of absolute risk difference 
indicated a less favourable safety profile of prolonged DAPT for older rather than younger patients.
Conclusions: In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly 
patients increased the risk of bleeding, without affording a significant prevention of ischaemic events.
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Abbreviations
BARC Bleeding Academic Research Consortium
CVA cerebrovascular accident
DAPT dual antiplatelet therapy
GUSTO Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries
MI myocardial infarction
PCI percutaneous coronary intervention
TIMI Thrombolysis In Myocardial Infarction
Introduction
Elderly individuals account for an increasing proportion of patients 
with coronary artery disease undergoing percutaneous coro-
nary intervention (PCI), due to the ageing of the population with 
increased life expectancy1-3. Dual antiplatelet therapy (DAPT) with 
aspirin and oral P2Y12 adenosine diphosphate receptor inhibitors 
represents the standard of treatment to prevent new atherothrom-
botic events after PCI, yet its optimal duration remains controver-
sial4-6. Results from randomised trials and meta-analyses indicate 
that extended (i.e., >12 months) duration of DAPT is associated 
with a lower risk of ischaemic events, even though this benefit 
is partly offset by a higher risk of clinically relevant bleeding7-9. 
However, extrapolating such findings to elderly patients is chal-
lenging in view of the increased risk of bleeding and ischaemic 
events occurring in this subgroup. In addition, elderly individuals 
have been underrepresented among randomised trials that evalu-
ated different durations of DAPT following PCI. The Prolonging 
Dual Antiplatelet Treatment After Grading Stent-Induced Intimal 
Hyperplasia Study (PRODIGY) compared a strategy of DAPT 
extended to 24 months with a shorter course of DAPT up to six 
months in a broadly inclusive population of PCI patients, with the 
inclusion of a relatively high proportion of elderly participants10.
Therefore, we sought to evaluate the impact of age in modu-
lating the hazard of ischaemic and bleeding events and to inves-
tigate the outcomes of 24-month vs. six-month DAPT in elderly 
(≥75 years) vs. younger patients (<75 years) enrolled in the 
PRODIGY trial.
Methods
Details on study design and primary results of the PRODIGY trial 
have been reported elsewhere10. Briefly, all-comer patients under-
going treatment with a balanced mixture of stents were randomly 
allocated at 30 days to either up to six months or to 24 months of 
DAPT. The ethics committees of the participating centres inde-
pendently approved the protocol and all participants gave written 
informed consent.
TREATMENT PROTOCOL
All patients received aspirin (80-160 mg orally indefinitely) and 
clopidogrel (75 mg/day) according to the randomisation scheme as 
follows: for either up to six months in the short DAPT group or to 
24 months in the prolonged DAPT arm, irrespective of the previ-
ously implanted stent type or indication for PCI.
STUDY ENDPOINTS
The primary efficacy endpoint of the PRODIGY trial was the 
composite of death, myocardial infarction (MI), or cerebrovas-
cular accident (CVA), whereas the key safety endpoint included 
Bleeding Academic Research Consortium (BARC) type 2, 3, or 
5 bleeding. Other endpoints included each component of the pri-
mary efficacy endpoint, cardiovascular death, stent thrombosis 
defined on the basis of the Academic Research Consortium crite-
ria, and BARC type 3 or 5 bleeding. Additional safety endpoints 
were bleeding events adjudicated according to the Thrombolysis 
In Myocardial Infarction (TIMI) and the Global Utilization of 
Streptokinase and Tissue Plasminogen Activator for Occluded 
Arteries (GUSTO) criteria. More detailed definitions of the end-
points have been provided previously11. A clinical events commit-
tee blinded to treatment allocation adjudicated all efficacy and 
bleeding events.
STATISTICAL ANALYSIS
Continuous variables are presented as mean±standard deviation 
and were compared with the Wilcoxon rank-sum test. Categorical 
variables are expressed as counts and percentages and were com-
pared with chi-square or Fisher’s exact tests as appropriate. We 
evaluated the effect of age, modulated as a continuous vari-
able, on the risk of ischaemic and bleeding events in the overall 
population by means of multivariable-adjusted, restricted cubic 
splines with three knots of the distribution (10th, 50th, and 90th 
percentiles)12. The effect of age on clinical events was analysed 
in the categories of patients <75 vs. ≥75 years by using Cox 
regression analyses. Both analyses were adjusted for baseline 
clinical variables associated with the primary efficacy and key 
safety endpoints at the univariate analysis with a significance 
level of p<0.20. The efficacy and safety of 24-month DAPT 
vs. six-month DAPT for elderly (≥75 years) vs. non-elderly 
(<75 years) patients was evaluated at 24 months. Clinical events 
were expressed as counts with rates computed according to the 
Kaplan-Meier method. Cox regression analysis was used to cal-
culate hazard ratios (HRs) with 95% confidence intervals (CIs) 
and an interaction test was provided to evaluate the effect of 
treatment in the elderly vs. non-elderly. Sensitivity analyses were 
conducted to evaluate the efficacy and safety of DAPT from six 
to 24 months by using a landmark analysis and to assess whether 
results were consistent by applying the cut-off of 65 years to 
define the elderly status. In addition, we evaluated the risk of 
deaths associated or not with MI if they occurred within a seven-
day window from MI onset. Risk difference and the number 
needed to treat for benefit or harm (NNTB or NNTH) with rela-
tive 95% CI were also provided in order to account for abso-
lute risk estimates. Finally, the interaction between treatment 
effect and ageing, modelled as a continuous variable, was ana-
lysed with a fractional polynomial interaction13. All p-values are 
two-sided and statistical significance was assumed for p<0.05. 
All analyses were carried out with Stata Statistical Software, 
Release 13 (StataCorp LP, College Station, TX, USA).
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Results
Of 1,970 participants enrolled in the PRODIGY trial, 587 (29.8%) 
patients were ≥75 years of age and 1,383 (70.2%) patients were 
<75 years of age. As shown in Table 1 and Table 2, baseline and 
periprocedural features were largely comparable within the elderly 
vs. non-elderly groups between patients assigned to 24-month or 
six-month DAPT.
EFFECT OF AGEING ON CLINICAL OUTCOMES
There was a direct graded relationship between age and the risks 
of the primary efficacy or the key safety endpoint, with a steeper 
increase in the hazard trajectories beyond 70 years of age (Figure 1). 
A similar direct association between age and bleeding events was 
observed for BARC type 3 or 5, TIMI minor or major, or GUSTO 
moderate or severe bleeding (data not shown). When dichotomised, 
patients with age ≥75 years compared with younger participants had 
a higher risk of death, MI or CVA and BARC type 2, 3 or 5 bleeding.
EFFICACY OF PROLONGED DAPT AMONG ELDERLY VS. 
NON-ELDERLY PATIENTS
Figure 2A shows the analysis of efficacy endpoints at two-year 
follow-up. There was a significant interaction (p=0.036) between 
Table 1. Baseline characteristics.
Age ≥75 years Age <75 years
p-interaction24-month 
DAPT
N=283
≤6-month 
DAPT
N=304
p-value
24-month 
DAPT
N=704
≤6-month 
DAPT
N=679
p-value
Age, years 80.2±3.7 80.6±4.3 0.47 62.9±9.1 62.3±8.7 0.07 0.19
Male 186 (65.7) 200 (65.8) 1.00 578 (82.1) 547 (80.6) 0.49 0.64
BMI, kg/m2 26.8±9.5 26.4±3.6 0.58 28.1±13.3 28.1±11.4 0.22 0.78
Hypertension 232 (82.0) 237 (78.0) 0.26 489 (69.5) 456 (67.2) 0.39 0.54
Dyslipidaemia 142 (50.2) 149 (49.0) 0.81 411 (58.4) 376 (55.4) 0.28 0.70
Smoking 18 (6.4) 29 (9.5) 0.17 204 (29.0) 218 (32.1) 0.22 0.38
Diabetes 83 (29.3) 82 (27.0) 0.58 161 (22.9) 151 (22.2) 0.80 0.72
Insulin-treated diabetes 17 (6.0) 22 (7.2) 0.62 42 (6.0) 33 (4.9) 0.41 0.31
Family history of CAD 70 (24.7) 39 (12.8) <0.001 219 (31.1) 225 (33.1) 0.42 <0.001
Previous MI 93 (32.9) 93 (30.6) 0.60 177 (25.1) 163 (24.0) 0.66 0.84
Previous PCI 47 (16.6) 64 (21.1) 0.17 142 (20.2) 106 (15.6) 0.03 0.018
Previous CABG 44 (15.5) 40 (13.2) 0.41 66 (9.4) 63 (9.3) 1.00 0.54
Creatinine clearance, mL/min 53.6±19.7 54.9±18.7 0.28 89.7±44.8 87.8±27.5 0.82 0.32
Peripheral artery disease 55 (19.4) 74 (24.3) 0.16 63 (8.9) 54 (8.0) 0.56 0.14
LVEF, % 49.8±10.6 48.5±11.0 0.12 51.5±10.0 51.4±10.1 0.92 0.20
Congestive HF or LV dysfunction 24 (8.5) 21 (6.9) 0.54 16 (2.3) 19 (2.8) 0.61 0.35
Indication to PCI 0.62 0.99 0.66
Stable CAD 56 (19.8) 58 (19.1) 0.84 199 (28.3) 192 (28.3) 1.00
NSTE-ACS 149 (52.7) 151 (49.7) 0.51 262 (37.2) 255 (37.6) 0.91
STEMI 78 (27.6) 95 (31.2) 0.37 243 (34.5) 232 (34.2) 0.91
Acute MI at presentation 162 (57.2) 188 (61.8) 0.27 385 (54.7) 363 (53.5) 0.67 0.23
Values are n (%) or mean±SD. BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; 
HF: heart failure; LV: left ventricular; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTE-ACS: non-ST-segment elevation acute 
coronary syndrome; STEMI: ST-segment elevation myocardial infarction.
Figure 1. Multivariable-adjusted spline curves for the HR of the 
primary ischaemic and bleeding endpoint vs. age modelled as 
a continuous variable. Patients with age ≤30 years represent the 
referent group with the HR set to 1. The dotted lines represent the 95% 
CI of the hazard function. The variables used for the adjustments are 
listed in the Methods section. BARC: Bleeding Academic Research 
Consortium; CI: confidence intervals; CVA: cerebrovascular 
accident; HR: hazard ratio; MI: myocardial infarction
81
EuroIntervention 2
0
17;1
3
:78
-8
6
DAPT in the elderly
age, dichotomised at age 75 years cut-off point, and the primary 
efficacy endpoint. Although the primary efficacy endpoint did not 
differ based on the randomly allocated DAPT duration among 
elderly patients, event rates were numerically lower for prolonged 
DAPT (HR 0.80, 95% CI: 0.55-1.16, p=0.24). Conversely, a trend 
towards an increased risk of the primary endpoint was observed 
among younger patients randomised to 24-month vs. six-month 
DAPT (HR 1.48, 95% CI: 0.95-2.30, p=0.08). This difference 
was mainly driven by cardiac mortality, which occurred more fre-
quently among younger patients randomised to 24-month DAPT 
(HR 2.92, 95% CI: 0.94-9.05, p=0.06). However, the age-by-
treatment interaction was significant for deaths not related to MI 
(p=0.043), but not for those related to MI (p=0.81). The test for 
interaction for the primary endpoint was not significant (p=0.10) 
from six to 24 months (Figure 2B). By using a cut-off of 65 years, 
there was no significant interaction (p=0.09) with 24-month vs. 
six-month DAPT with respect to the primary ischaemic endpoint 
among patients ≥65 years (HR 0.89, 95% CI: 0.66-1.21, p=0.48) 
vs. those <65 years (HR 1.75, 95% CI: 0.86-3.58, p=0.13).
SAFETY OF PROLONGED DAPT AMONG ELDERLY VS. 
NON-ELDERLY PATIENTS
Figure 3A shows the analysis of safety endpoints at two-year follow-
up. BARC type 2, 3 or 5 bleeding was significantly increased in both 
elderly (HR 1.90, 95% CI: 1.06-3.38, p=0.03) and non-elderly patients 
(HR 2.54, 95% CI: 1.43-4.53, p=0.002; p for interaction=0.48) ran-
domised to 24-month versus six-month DAPT. The NNTH was 
lower for elderly (NNTH 18; 95%CI: NNTH 119 to NNTH 10) than 
for non-elderly patients (NNTH 29; 95%CI: NNTH 72 to NNTH 
18). Although not significantly increased, bleeding events accord-
ing to TIMI and GUSTO definitions were numerically higher in 
patients randomised to 24-month DAPT vs. six-month DAPT. In the 
analysis between six and 24 months (Figure 3B), the relative risks 
of BARC type 2, 3 or 5 bleeding were consistently higher in both 
patients aged ≥75 years (HR 2.73, 95% CI: 1.26-5.89, p=0.01) and 
patients <75 years (HR 2.73, 95% CI: 1.37-5.44, p=0.004, p for 
interaction=0.99). The corresponding NNTH for the two groups was 
18 (95%CI: NNTH 89 to NNTH 11) and 36 (95%CI: NNTH 107 
to NNTH 21), respectively. After six months, moderate or severe 
Table 2. Angiographic and procedural characteristics.
Age ≥75 years Age <75 years
p-interaction24-month 
DAPT
N=283
≤6-month 
DAPT
N=304
p-value
24-month 
DAPT
N=704
≤6-month 
DAPT
N=679
p-value
Angiographic features 0.09 0.73 0.08
Single-vessel disease 58 (20.5) 79 (26.0) 234 (33.2) 220 (32.4)
Two-vessel disease 84 (29.7) 100 (32.9) 267 (37.9) 250 (36.8)
Three-vessel disease 141 (49.8) 125 (41.1) 203 (28.8) 209 (30.8)
Multivessel disease 225 (79.5) 225 (74.0) 0.12 470 (66.8) 459 (67.6) 0.78 0.13
Multivessel PCI 88 (31.1) 98 (32.2) 0.79 165 (23.4) 175 (25.8) 0.32 0.74
≥2 treated lesions 116 (41.0) 127 (41.8) 0.87 249 (35.4) 244 (35.9) 0.87 0.97
≥3 treated lesions 33 (11.7) 32 (10.5) 0.69 75 (10.7) 83 (12.2) 0.40 0.39
≥4 treated lesions 10 (3.5) 14 (4.6) 0.54 28 (4.0) 30 (4.4) 0.69 0.74
Treated vessel
Left anterior descending artery 151 (53.4) 161 (53.0) 0.93 367 (52.1) 357 (52.6) 0.87 0.86
Left circumflex artery 113 (39.9) 93 (30.6) 0.02 208 (29.5) 225 (33.1) 0.16 0.006
Right coronary artery 86 (30.4) 113 (37.2) 0.10 260 (36.9) 250 (36.8) 1.00 0.14
Left main artery 24 (8.5) 24 (7.9) 0.88 31 (4.4) 32 (4.7) 0.80 0.71
Saphenous vein graft 7 (2.5) 7 (2.3) 1.00 16 (2.3) 10 (1.5) 0.32 0.59
At least one type B2/C lesion 185 (65.4) 221 (72.7) 0.06 457 (64.9) 443 (65.2) 0.91 0.12
At least one restenotic lesion 7 (2.5) 15 (4.9) 0.13 38 (5.4) 33 (4.9) 0.72 0.12
Randomised stent 0.58 0.88 0.45
Bare metal stent 82 (29.0) 80 (26.3) 164 (23.3) 166 (24.4)
Paclitaxel-eluting stent 66 (23.3) 68 (22.4) 182 (25.9) 177 (26.1)
Zotarolimus-eluting stent 59 (20.8) 78 (25.7) 186 (26.4) 167 (24.6)
Everolimus-eluting stent 76 (26.9) 78 (25.7) 172 (24.4) 169 (24.9)
Number of implanted stents 1.9±1.3 1.9±1.0 0.22 1.8±1.2 1.9±1.3 0.52 0.59
Overall stent length, mm* 38.6±28.8 39.3±24.3 0.26 39.3±30.8 40.5±30.5 0.53 0.87
Mean stent diameter, mm* 2.9±0.4 3.0±0.4 0.04 3.0±0.5 3.0±0.5 0.008 0.004
All data are shown per patient. *Information available in 1,964 patients. DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention
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bleeding according to GUSTO criteria was significantly increased in 
elderly but not in younger patients treated with 24-month DAPT. The 
corresponding NNTH was NNTH 24 (95%CI: NNTH 78 to NNTH 
13) for older vs. NNTH 194 (95%CI: NNTB 198 to NNTH 58) for 
younger patients. A significant interaction (p=0.007) for the absolute 
risk difference of moderate or severe GUSTO bleeding was present 
between older (3.9%, 95% CI: 1.1-6.8%) and younger groups (0.04%, 
95% CI: -0.06%–1.5%) after six-month follow-up. By using a cut-
off of 65 years, there was no significant interaction (p=0.49) with 
24-month vs. six-month DAPT with respect to the primary bleed-
ing endpoint among patients ≥65 years (HR 1.96, 95% CI: 1.23-3.31, 
p=0.004) vs. those <65 years (HR 2.92, 95% CI: 1.23-6.96, p=0.02).
INTERACTION BETWEEN AGEING AND TREATMENT EFFECT 
OF DAPT
The age-by-treatment interaction evaluated by fractional polyno-
mial analyses was not significant for the primary efficacy (p=0.35) 
and key safety endpoints (p=0.73). For the composite of death, MI 
or CVA, the area representing the 95% CI treatment effect crossed 
the no effect line throughout all ages (Figure 4A). In contrast, the 
area of treatment effect for the key safety endpoint was above the 
line of no effect for a wide range of ages, indicating a harmful 
effect of 24-month over six-month DAPT in terms of bleeding 
complications for most age values (Figure 4B).
Discussion
The main findings of the present analysis of the PRODIGY trial 
can be summarised as follows.
1) Elderly patients undergoing PCI have a higher risk of ischae-
mic and bleeding events compared with younger patients, with 
a similar effect of ageing on the hazards of such events.
2) In both elderly and non-elderly patients, prolonging DAPT for 
24 months did not reduce the risk of the primary efficacy end-
point of death, MI or CVA compared with a six-month DAPT.
Figure 2. Analysis of efficacy outcomes stratified by age. A) Ischaemic events at 24 months. B) Ischaemic events from six to 24 months. CI: confidence 
intervals; CVA: cerebrovascular accident; DAPT: dual antiplatelet therapy; HR: hazard ratio; MI: myocardial infarction; ST: stent thrombosis
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Figure 3. Analysis of safety outcomes stratified by age. A) Bleeding events at 24 months. B) Bleeding events from six to 24 months. BARC: 
Bleeding Academic Research Consortium; GUSTO: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
Arteries; TIMI: Thrombolysis In Myocardial Infarction
Figure 4. Fractional polynomial interaction for the primary efficacy and key safety endpoints. A) Death, MI or CVA. B) BARC type 2, 3 or 5 
bleeding. The treatment-by-age interaction is analysed by considering age as a continuous variable. The green line represents the treatment 
effect of 24-month vs. six-month DAPT and the area represents the 95% CI of treatment effect. The dotted red line represents the no treatment 
effect. The comparison of 24-month vs. six-month DAPT is significant for the age values where the green area does not cross the line of no 
treatment effect. In this case, the effect of prolonged DAPT in increasing the risk of the key safety endpoint was significant for the range of 50 
to 80 years.
3) A strategy of 24-month DAPT compared with six-month DAPT 
was associated with a greater risk of the key safety endpoint 
of BARC type 2, 3 or 5 bleeding in both elderly and non-
elderly patients. Although the relative magnitude of treatment 
effect on bleeding was similar, the absolute risk difference with 
prolonged DAPT was greater in elderly compared with younger 
participants.
DAPT is an evidence-based, guideline-recommended, standard 
of care treatment after PCI14. Recently, two large randomised tri-
als, DAPT and PEGASUS-TIMI 54 (Prevention of cardiovascular 
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events in patients with prior heart attack using ticagrelor compared 
to placebo on a background of aspirin–thrombolysis in myocardial 
infarction 54), showed a significant reduction in ischaemic events 
with long-term DAPT among patients undergoing PCI as well as 
among high-risk patients with prior myocardial infarction7,9,15,16. 
Nevertheless, the optimal treatment duration of DAPT remains con-
troversial as the protection afforded by extended DAPT in terms 
of ischaemic events is counterbalanced by an increase in bleeding 
complications7,8. Although the PEGASUS-TIMI 54 trial reported 
consistent results in terms of the primary ischaemic endpoint accord-
ing to age, elderly patients represented less than 15% of the overall 
population15. However, despite being formally not significant (p for 
interaction=0.09), elderly versus non-elderly patients derived less 
ischaemic benefit from 90 mg of ticagrelor vs. placebo. At variance, 
among participants allocated to ticagrelor 60 mg, elderly patients 
derived a similar magnitude of benefit to non-elderly patients with 
regard to the primary efficacy endpoint. A treatment-by-age hetero-
geneity for the primary endpoint according to age has been observed 
in the ISAR-SAFE (p for interaction=0.03) and IVUS-XPL trials 
(p for interaction=0.051), favouring the use of short-term DAPT in 
elderly rather than younger patients17,18. However, the primary end-
point in both trials included a composite of ischaemic and bleeding 
events, which did not allow complete assessment of the benefit-risk 
ratio associated with DAPT in elderly patients.
We found that elderly patients experienced a greater risk of both 
ischaemic and bleeding events, with risk trajectories proceeding 
similarly with ageing. Such a pattern is similar to that described 
by Roe and colleagues in a cohort of patients with acute coronary 
syndrome managed without revascularisation19. Prolonged DAPT 
did not reduce the risk of ischaemic events among both elderly 
and non-elderly patients, which is in keeping with the results in the 
overall finding of the PRODIGY trial. However, interaction test-
ing showed heterogeneity in treatment effect for the primary effi-
cacy endpoint, with a possible harmful effect with 24-month DAPT 
in non-elderly subjects. In this regard, the higher risk of cardiac 
instead of non-cardiac death among younger patients randomised 
to 24-month DAPT, although not related to MI, remains biologi-
cally counterintuitive and difficult to explain. Such a finding could 
also be the result of variable categorisation rather than a direct 
effect, because the age-by-treatment interaction on a continuous 
basis was not significant at the fractional polynomial analysis.
Our study provides a nuanced interpretation for the alleged dif-
ference in the risk of bleeding associated with DAPT use among 
elderly patients. We found that prolonged DAPT had a similar 
effect on the key bleeding endpoint of BARC type 2, 3 or 5 among 
elderly and non-elderly patients at 24-month follow-up. However, 
owing to the higher rate of bleeding events, elderly patients had 
a greater increase in the absolute risk of BARC 2, 3 or 5 bleed-
ing with 24-month DAPT, resulting in a lower NNTH (18 vs. 
29). During the period between six and 24 months, the absolute 
risk difference in BARC 2, 3 or 5 bleeding tended to increase, as 
well as the difference in the NNTH (18 vs. 36). Taken together, 
these findings suggest that relative and absolute risks of bleeding 
should be disentangled in the decision process for DAPT duration 
in elderly people, by factoring the similar relative risk of bleeding 
associated with prolonged DAPT with the higher absolute risk dif-
ference due to the increased event rate.
Limitations
The results of this study have to be interpreted in the light of several 
limitations. First, our observations are based on subgroup popula-
tions within an overall trial, which failed to show the superiority of 
prolonged DAPT in the main population. Second, although there is 
general agreement that people ≥75 years can be defined as “elderly”, 
ageing is a continuous process and the cut-off of 75 years remains 
arbitrary. Nevertheless, we tried to accommodate this limitation 
by evaluating the age-by-treatment interaction also on a continu-
ous basis. Furthermore, a cut-off of 65 years yielded similar results. 
Third, the group of elderly patients was relatively modest in size, 
and all the analyses should be considered as hypothesis-generating 
and exploratory in nature. However, it is noteworthy that the mean 
age in the PRODIGY trial was the highest across available trials 
with comparable design. This might explain the differential effect of 
elderly status on the risk of ischaemic events observed in this study 
compared with other trials enrolling relatively younger patients. 
Fourth, randomisation in the PRODIGY trial was not stratified by age.
Conclusions
In an all-comers population of PCI patients, elderly participants 
experienced a higher risk of ischaemic and bleeding events com-
pared with their non-elderly counterparts with a comparable effect 
of ageing on the hazards of such events. Prolonging DAPT for 
24 months was not associated with a significantly different risk 
of the primary efficacy endpoint among elderly and non-elderly 
patients. However, elderly patients seemed to derive a greater 
absolute risk of clinically relevant bleeding from prolonged DAPT 
than younger patients.
Impact on daily practice
Elderly status conveys a higher risk of both ischaemic and 
bleeding events. Although dual antiplatelet therapy increases 
the risk of bleeding in both elderly and non-elderly patients, the 
former group incurs a substantially higher event rate. The effi-
cacy of prolonged dual antiplatelet therapy for the prevention of 
ischaemic events is not influenced by elderly status.
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